PHILADELPHIA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Fortress Biotech, Inc. (“Fortress Biotech” or the “Company”) (NASDAQ: FBIO) to determine whether the Company engaged in securities fraud or other unlawful business practices. INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, THE SECURITIES OF FORTRESS BIOTECH BETWEEN DECEMBER 11, 2019 AND OCTOBER 9, 2020, BOTH DATES INCLUSIVE (THE “CLASS PERIOD”), AND SUFFERED LOSSES GREATER THAN $50,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE OR CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, MYARNOFF@KEHOELAWFIRM.COM, SECURITIES@KEHOELAWFIRM.COM, TO DISCUSS THE SECURITIES INVESTIGATION OR POTENTIAL LEGAL CLAIMS. On November 27, 2020, a class action lawsuit was filed against Fortress Biotech in United States District Court, Eastern District of New York. According to the class action complaint, throughout the Class Period, the Fortress Biotech Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, according to the class action complaint, the Fortress Biotech Defendants made false and/or misleading statements and/or failed to disclose that IV Tramadol was not safe for the intended patient population, and that it was foreseeable to them that the FDA would not approve the New Drug Application for IV Tramadol.Kehoe Law Firm, P.C., with offices in New York and Philadelphia, is a multidisciplinary, plaintiff–side law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion on behalf of institutional and individual investors.This press release may constitute attorney advertising.
NEW YORK, NY / ACCESSWIRE / November 30, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fortress Biotech, Inc.
Pomerantz LLP announces that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress" or the "Company") (NASDAQ: FBIO) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05767, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fortress securities between December 11, 2019 and October 9, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.